Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production
Immunity · 2024-03 · 57 (3) · 446-461.e7
DOI: 10.1016/j.immuni.2024.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2024-03. Verfasst von Munesh K Harioudh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: 2',5'-Oligoadenylate Synthetase, Interferons, Oligoribonucleotides, Virus Diseases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
In response to viral infection, how cells balance translational shutdown to limit viral replication and the induction of antiviral components like interferons (IFNs) is not well understood. Moreover, how distinct isoforms of IFN-induced oligoadenylate synthetase 1 (OAS1) contribute to this antiviral response also requires further elucidation. Here, we show that human, but not mouse, OAS1 inhibits SARS-CoV-2 replication through its canonical enzyme activity via RNase L. In contrast, both mouse and human OAS1 protect against West Nile virus infection by a mechanism distinct from canonical RNase L activation. OAS1 binds AU-rich elements (AREs) of specific mRNAs, including IFNβ. This binding leads to the sequestration of IFNβ mRNA to the endomembrane regions, resulting in prolonged half-life and continued translation. Thus, OAS1 is an ARE-binding protein with two mechanisms of antiviral activity: driving inhibition of translation but also a broader, non-canonical function of protecting IFN expression from translational shutdown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.
- Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Immunology, School of Medicine, University of Washington, Seattle, WA, USA; Division of Immunology, Benaroya Research Institute, Seattle, WA, USA.
- Department of Immunology, School of Medicine, University of Washington, Seattle, WA, USA.
- Department of Biochemistry, Ludwig Maximilians Universität, Munich, Germany.
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Merck
- Oklahoma Academy of Science
- National Institutes of Health
Zitieren
APA
Harioudh, M. K., Perez, J., Chong, Z., Nair, S., So, L., McCormick, K. D., Ghosh, A., Shao, L., Srivastava, R., Soveg, F., Ebert, T. S., Atianand, M. K., Hornung, V., Savan, R., Diamond, M. S., & Sarkar, S. N. (2024). Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production. Immunity, 57(3), 446-461.e7. https://doi.org/10.1016/j.immuni.2024.02.002
Vancouver
Harioudh MK, Perez J, Chong Z, Nair S, So L, McCormick KD, et al. Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production. Immunity. 2024;57(3):446-461.e7. doi:10.1016/j.immuni.2024.02.002
BibTeX
@article{Harioudh2024,
author = {Harioudh, Munesh K and Perez, Joseph and Chong, Zhenlu and Nair, Sharmila and So, Lomon and McCormick, Kevin D and Ghosh, Arundhati and Shao, Lulu and Srivastava, Rashmi and Soveg, Frank and Ebert, Thomas S and Atianand, Maninjay K and Hornung, Veit and Savan, Ram and Diamond, Michael S and Sarkar, Saumendra N},
title = {Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production},
journal = {Immunity},
year = {2024},
volume = {57},
number = {3},
pages = {446--461.e7},
doi = {10.1016/j.immuni.2024.02.002}
}
EUVIMED